Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710720 | 0.81 | NOTUM (0.46) | NOTUMHRH3PIK3CDTSHRKDM2B | |
| SCHEMBL19702011 | 0.81 | NOTUM (0.51) | NOTUMHRH3GRM2 | |
| SCHEMBL19702015 | 0.80 | NOTUM (0.50) | NOTUMHRH3PIK3CDGRM2VCP | |
| SCHEMBL19702010 | 0.79 | NOTUM (0.50) | NOTUMHRH3PIK3CDGRM2 | |
| SCHEMBL26498532 | 0.78 | NOTUM (0.55) | NOTUMHRH3GRM2OPRM1OPRD1 | |
| SCHEMBL22055865 | 0.77 | L3MBTL3 (0.53) | NOTUMHRH3MBTD1L3MBTL3OPRM1 | |
| SCHEMBL24243095 | 0.77 | NOTUM (0.54) | NOTUMHRH3POLBTSHRMBTD1 | |
| SCHEMBL19702013 | 0.77 | BPTF (0.57) | NOTUMHRH3 | |
| SCHEMBL23510803 | 0.76 | NOTUM (0.46) | NOTUMHRH3MBTD1L3MBTL3OPRM1 | |
| SCHEMBL25752839 | 0.76 | NOTUM (0.55) | NOTUMHRH3TSHRGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | NOTUM 3221/4885HRH3 61/4885POLB 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.